N. Sasaki

发表

Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.

M. Taniwaki, J. Kuroda, Y. Shimura, 2012, Current cancer drug targets.

Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia

T. Taki, M. Taniwaki, S. Horiike, 2011, Proceedings of the National Academy of Sciences.

Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma

M. Taniwaki, H. Kaneko, J. Kuroda, 2022, Leukemia & lymphoma.

Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation

M. Taniwaki, S. Horiike, J. Kuroda, 2013, International Journal of Hematology.

Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality

T. Taki, M. Taniwaki, S. Horiike, 2013, Leukemia & lymphoma.

Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.

M. Taniwaki, S. Horiike, J. Kuroda, 2016, Internal medicine.

Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia

M. Taniwaki, A. Yamauchi, S. Kimura, 2010, Molecular Cancer Research.

Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients

M. Taniwaki, H. Kaneko, J. Kuroda, 2019, International Journal of Hematology.

Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome

M. Taniwaki, S. Horiike, J. Kuroda, 2014, Case Reports in Oncology.

Thrombotic thrombocytopenic purpura associated with myelodysplastic syndrome

M. Taniwaki, J. Kuroda, E. Kawata, 2008, International journal of hematology.

Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations

J. Kuroda, Y. Tsutsumi, Y. Nannya, 2021, Annals of Hematology.

Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma

T. Taki, M. Taniwaki, S. Horiike, 2021, Journal of clinical and experimental hematopathology : JCEH.

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma

M. Taniwaki, S. Horiike, J. Kuroda, 2012, International Journal of Hematology.

Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma

T. Taki, M. Taniwaki, S. Horiike, 2019, International Journal of Hematology.

Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.

Y. Akao, T. Taki, M. Taniwaki, 2011, Experimental hematology.

Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.

M. Taniwaki, S. Horiike, J. Kuroda, 2010, Leukemia research.

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience

M. Taniwaki, S. Horiike, J. Kuroda, 2010, International journal of hematology.

Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis.

M. Taniwaki, S. Horiike, J. Kuroda, 2010, American journal of clinical pathology.

Cyclosporine A for Chemotherapy-Resistant Subcutaneous Panniculitis-Like T Cell Lymphoma with Hemophagocytic Syndrome

M. Taniwaki, S. Horiike, J. Kuroda, 2011, Acta Haematologica.

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients

M. Taniwaki, H. Kaneko, S. Horiike, 2021, Cancer reports.

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study

M. Taniwaki, H. Kaneko, J. Kuroda, 2022, International Journal of Hematology.

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors

M. Taniwaki, S. Horiike, J. Kuroda, 2013, Apoptosis.

Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma

M. Taniwaki, H. Kaneko, J. Kuroda, 2019, Annals of Hematology.

Expression of Master Regulators of Helper T-Cell Differentiation in Peripheral T-Cell Lymphoma, Not Otherwise Specified by Immunohistochemical Analysis.

M. Taniwaki, S. Horiike, J. Kuroda, 2009 .